Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) Meeting Abstract

  

Authors:	Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L.; Oh, D.; Omori, T.; Moehler, M. H.; Garrido, M.; Oliveira, S. S. C.; Liberman, M.; Oliden, V. C.; Smyth, E. C.; Serrano, O.; Heilbron, E.; Negro, A.; Tabernero, J.
Abstract Title:	Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
Meeting Title:	2025 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	17 Suppl.
Meeting Dates:	2025 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-06-10
Start Page:	LBA5
Language:	English
ACCESSION:	WOS:001511770100001
DOI:	10.1200/JCO.2025.43.17_suppl.LBA5
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/227111